Release Date: January 31, 2023
Expiration Date: January 31, 2024
Activity Overview
Immunoglobulin (Ig) A nephropathy (IgAN) is the most common form of primary glomerulonephritis worldwide, and it is considered a significant cause of end-stage renal disease (ESRD) in young adults. The precise pathogenesis of IgAN remains unclear. The clinical and pathological features vary significantly between individuals and races, which makes treating IgAN challenging. In most cases, the therapeutic strategies in IgAN are optimal blood pressure control and proteinuria remission to improve the renal functions. Immunosuppressive agents, such as corticosteroids, can be considered in patients with persistent proteinuria and a high risk of renal function decline; however, they include a high toxicity profile.
Various pharmacological therapeutic targets are emerging based on the evolving understanding of the autoimmune pathogenesis of the progression of IgAN, which involves the immune response, mucosal immunity, renal inflammation, complement activation, and autophagy. In this online activity, expert faculty provide information to help health care providers stay up to date on recent findings regarding the pathophysiology of IgAN, and the efficacy and safety profiles of available and emerging agents.
Target Audience
This activity is intended for nephrologists, primary care providers, specialty pharmacists, managed care professionals, nurse practitioners, physician assistants, registered nurses, and other members of the IgAN care team.
Learning Objectives
Upon successful completion of this activity, you should be better prepared to:
- Assess the pathophysiology of the disease progression of IgAN as potential targets for novel therapy
- Summarize recent evidence-based guidelines for the management of IgAN
- Analyze recent efficacy and safety trial data on new and emerging treatment for IgAN
- Design individualized treatment plans for patients with IgAN based on principles of multidisciplinary care
GET STARTED WITH THIS PROGRAM:
Register now to gain access to this program.
Create AccountAlready Registered? Login Here
Accreditation/Credit Designation
Physicians’ Education Resource®, LLC, is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Physicians’ Education Resource®, LLC, designates this enduring material for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Physicians’ Education Resource®, LLC is approved by the California Board of Registered Nursing, Provider #16669, for 1.5 Contact Hours.
Pharmacy Times Continuing Education™ is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. This activity is approved for 1.5 contact hours (0.10 CEUs) under the ACPE universal activity number 0290-0000-23-023-H01-P. The activity is available for CE credit through January 31, 2024.
Acknowledgment of Educational Grant Support
This activity is supported by an educational grant from Travere Therapeutics.
